The remarkable therapeutic effect of T-DM1 combined with osimertinib in EGFR-mutated or HER2-overexpressing NSCLC cell lines was shown by Silvia La Monica et al. and validated by several other researchers over the years. This evidence concerns the gene EGFR and non-small cell lung carcinoma.